Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Dror Ben-Asher
|
| gptkbp:country |
gptkb:Israel
|
| gptkbp:focusesOn |
infectious diseases
gastrointestinal diseases |
| gptkbp:foundedYear |
2009
|
| gptkbp:headquartersLocation |
gptkb:Tel_Aviv,_Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
RedHill Biopharma
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:Tel_Aviv_Stock_Exchange
|
| gptkbp:notableProduct |
gptkb:Movantik
Talicia Aemcolo Opaganib |
| gptkbp:numberOfEmployees |
approximately 100
|
| gptkbp:researchArea |
gptkb:COVID-19_treatments
oncology |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RDHL
|
| gptkbp:website |
https://www.redhillbio.com/
|
| gptkbp:bfsParent |
gptkb:Movantik
|
| gptkbp:bfsLayer |
7
|